These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 25592062)

  • 21. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
    Corcoran C; Rani S; O'Driscoll L
    Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNAs as therapeutic targets for lung cancer.
    Cho WC
    Expert Opin Ther Targets; 2010 Oct; 14(10):1005-8. PubMed ID: 20854177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
    Oxnard GR
    Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP).
    Wang Q; Zhong M; Liu W; Li J; Huang J; Zheng L
    Exp Lung Res; 2011 Sep; 37(7):427-34. PubMed ID: 21787234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation Mechanism of MicroRNAs in Non-Small Cell Lung Cancer.
    Gong FY; Bai T; Zhang DY; Huang CL; Lv J; Wang JL; Hu XD; Wang J; Liu W
    Curr Pharm Des; 2018 Feb; 23(39):5973-5982. PubMed ID: 28714412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells.
    An IS; An S; Kwon KJ; Kim YJ; Bae S
    Oncol Rep; 2013 Feb; 29(2):523-8. PubMed ID: 23152132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
    Rosell R; Cuello M; Cecere F; Santarpia M; Reguart N; Felip E; Taron M
    Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells.
    Chen Z; Ma T; Huang C; Zhang L; Lv X; Xu T; Hu T; Li J
    Cell Signal; 2013 Dec; 25(12):2693-701. PubMed ID: 24018051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNAs in melanoma development and resistance to target therapy.
    Fattore L; Costantini S; Malpicci D; Ruggiero CF; Ascierto PA; Croce CM; Mancini R; Ciliberto G
    Oncotarget; 2017 Mar; 8(13):22262-22278. PubMed ID: 28118616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer.
    Zhong M; Ma X; Sun C; Chen L
    Chem Biol Interact; 2010 Mar; 184(3):431-8. PubMed ID: 20097187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alteration of miRNA profiles by ionizing radiation in A549 human non-small cell lung cancer cells.
    Shin S; Cha HJ; Lee EM; Lee SJ; Seo SK; Jin HO; Park IC; Jin YW; An S
    Int J Oncol; 2009 Jul; 35(1):81-6. PubMed ID: 19513554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNAs as new therapeutic targets and tools in cancer.
    Gandellini P; Profumo V; Folini M; Zaffaroni N
    Expert Opin Ther Targets; 2011 Mar; 15(3):265-79. PubMed ID: 21208133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNAs in human lung cancer.
    Kang SM; Lee HJ
    Exp Biol Med (Maywood); 2014 Nov; 239(11):1505-13. PubMed ID: 24872439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNAs in cancer drug resistance: Basic evidence and clinical applications.
    Ghasabi M; Mansoori B; Mohammadi A; Duijf PH; Shomali N; Shirafkan N; Mokhtarzadeh A; Baradaran B
    J Cell Physiol; 2019 Mar; 234(3):2152-2168. PubMed ID: 30146724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel insights into the role of microRNA in lung cancer resistance to treatment and targeted therapy.
    Gong Z; Yang J; Li J; Yang L; Le Y; Wang S; Lin HK
    Curr Cancer Drug Targets; 2014; 14(3):241-58. PubMed ID: 24605945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types.
    Hummel R; Hussey DJ; Haier J
    Eur J Cancer; 2010 Jan; 46(2):298-311. PubMed ID: 19948396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance-related microRNAs in hematological malignancies: translating basic evidence into therapeutic strategies.
    Xie L; Jing R; Qi J; Lin Z; Ju S
    Blood Rev; 2015 Jan; 29(1):33-44. PubMed ID: 25263425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miRNA control of apoptotic programs: focus on ovarian cancer.
    Mezzanzanica D; Canevari S; Cecco LD; Bagnoli M
    Expert Rev Mol Diagn; 2011 Apr; 11(3):277-86. PubMed ID: 21463237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.